# Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

> **NCT00705822** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 54 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Docetaxel + Estramustine + Hydrocortisone
- **DRUG:** Docetaxel + Prednisone

## Key facts

- **NCT ID:** NCT00705822
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** low recruitment rate
- **Last updated:** 2010-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705822, "Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00705822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*